Soligenix Stock Price Forecast. Should You Buy SNGX?

'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberg

Diane L. Parks surrenders options on 566 Soligenix (SNGX) shares for no payment.

Radiotherapy-Induced Oral Mucositis Market Set for Strong Growth Through 2036, Driven by Emerging Therapies and Rising Cancer Burden | DelveInsight

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine

Soligenix culls topical lymphoma asset after Phase III miss

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

SNGX Forecast — Price Target — Prediction for 2027

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month On Ebola Vaccine Optimism

Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo V

Soligenix more than doubles as traders react to Ebola-outbreak vaccine-platform update

Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy